Lactam-containing compounds and derivatives thereof as factor Xa inhibitors

Details for Australian Patent Application No. 2002341693 (hide)

Owner Bristol-Myers Squibb Company

Inventors Han, Wei; Li, Yun-Long; Lam, Patrick; Quan, Mimi; Koch, Stephanie; Qiao, Jennifer; Orwat, Michael; Pinto, Donald

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2002341693

PCT Number PCT/US02/29491

PCT Pub. Number WO2003/026652

Priority 60/324,165 21.09.01 US

Filing date 17 September 2002

Wipo publication date 7 April 2003

Acceptance publication date 29 May 2008

International Classifications

C07D 401/10 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/437 (2006.01)

A61K 31/4439 (2006.01)

A61K 31/444 (2006.01)

A61K 31/4545 (2006.01)

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 471/16 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

27 February 2003 Complete Application Filed

  Priority application(s): 60/324,165 21.09.01 US

26 June 2003 Application Open to Public Inspection

  Published as AU-B-2002341693

29 May 2008 Application Accepted

  Published as AU-B-2002341693

25 September 2008 Standard Patent Sealed

6 October 2011 Extension of Term of Standard Patents

  Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 21 Jul 2011 For the goods ELIQUIS apixaban

27 October 2011 Extension of Term of Standard Patents

  Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 21 Jul 2011 For the goods ELIQUIS apixaban Address for service in Australia: Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000

22 March 2012 Extension granted

  Bristol-Myers Squibb Company The earliest first regulatory approval date provided by the patentee 21 Jul 2011 For the goods ELIQUIS apixaban Extension of Term of patent pursuant to Section 77 expires on 21 Jul 2026

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002341694-PROCESS FOR CLEANING COMPONENTS USING CLEANING MEDIA

2002341692-MULTILINGUAL DATABASE CREATION SYSTEM AND METHOD